Icagen, Inc. announced that the company has completed the acquisition of Sanofi's ultra high-throughput biology, screening and chemistry capabilities and research facility in Oro Valley, Arizona (located near Tucson, Arizona) . The acquisition includes an agreement between Icagen and Sanofi to collaborate in a multi-year services contract for long term discovery services.
As part of its growth plans, the deal will enable Icagen to enhance its current expertise as a specialized pharmaceutical services company with leading capabilities in ion channels and transporters. "The acquisition of Sanofi's west coast ultra high throughput screening biology and chemistry capabilities complements our scientific expertise enabling us to offer a broad range of integrated drug discovery services in a growing market," says Icagen president and CEO, Richard Cunningham.
As part of the agreement, Icagen will manage an extensive Sanofi compound library, making it accessible, under specific conditions, to a broader number of partners and increasing the potential for drug discovery. "The scientists at the Oro Valley site bring a high level of proficiency in synthetic and computational chemistry, and additional capabilities for rare disease biology and phenotypic screening," commented Douglas Krafte, chief scientific officer at Icagen in a preliminary announcement of the deal.
The Oro Valley HTS and Compound Management Center has roots as a University of Arizona start-up. The facility has been in operation since 1990, and has built a large novel proprietary collection of drug like compounds over the decades. The facility was originally privately acquired by MMD in 1995. Specifically, services at the site include, discovery biology, chemistry and, compound management and computational chemistry. The site also provides capacity in cell models, human biomarkers, muscle biology expertise and stem cells-based assays. The facility also features high volume biology with a flexible robotic infrastructure capable of performing HTS in Ultra High 1536 format.
Icagen partners with pharmaceutical and biotechnology companies to offer industry-leading scientific expertise and comprehensive access to technologies for ion channel and transporter drug discovery and development.